The dynamic changes of circulating invariant natural killer T cells during chronic hepatitis B virus infection

Hepatol Int. 2016 Jul;10(4):594-601. doi: 10.1007/s12072-015-9650-0. Epub 2016 Feb 26.

Abstract

Aim: The protective role of invariant natural killer T cells (iNKTs) against hepatitis B virus (HBV) infection remains controversial. We sought to clarify the role of peripheral iNKT cells during chronic HBV infection.

Methods: Sixty patients with chronic HBV infection were categorized into an immune tolerance phase (HBV-IT) (n = 16), an immune clearance phase (HBV-IC) (n = 19) and an inactive carrier phase (HBV-IA) (n = 25). Twenty healthy individuals were enrolled as healthy controls. Another 21 HBeAg-positive patients were administrated with entecavir (0.5 mg/day) for 6 months. The percentages of circulating iNKT cells and their IFN-γ and IL-4 expression levels were examined by flow cytometry. The relationships between serum HBV DNA, ALT levels, the percentages of iNKT cells, and their IFN-γ and IL-4 levels were analyzed.

Results: Compared to healthy controls, the percentage of iNKT cells decreased in HBV-IT, but increased in HBV-IC and HBV-IA. Circulating IFN-γ-producing iNKT cells gradually increased, whereas IL-4-producing iNKT cells gradually decreased from HBV-IT stage to HBV-IC and HBV-IA stages. The frequency of iNKT cells and their IFN-γ levels were reversely correlated with viral load. The levels of IL-4 expressed by iNKT cells were positively correlated to viral load and the serum ALT levels. After anti-virus therapy, the percentage of IFN-γ-producing iNKT cells increased while the percentage of IL-4-producing iNKT cells decreased.

Conclusions: During chronic HBV infection, the percentages of peripheral iNKT cells and its cytokines expressions of IFN-γ and IL-4 showed dynamic changes. The expression levels of IFN-γ and IL-4 were correlated with the clearance of HBV and liver injury.

Keywords: Chronic HBV infection; IFN-γ; IL-4; iNKTs.

MeSH terms

  • Adult
  • Antiviral Agents / administration & dosage
  • Case-Control Studies
  • DNA, Viral / blood
  • Female
  • Guanine / administration & dosage
  • Guanine / analogs & derivatives
  • Hepatitis B e Antigens / immunology
  • Hepatitis B virus / drug effects
  • Hepatitis B virus / genetics
  • Hepatitis B virus / immunology*
  • Hepatitis B, Chronic / blood
  • Hepatitis B, Chronic / drug therapy
  • Hepatitis B, Chronic / immunology*
  • Humans
  • Interferon-gamma / biosynthesis
  • Interferon-gamma / immunology
  • Interleukin-4 / biosynthesis
  • Interleukin-4 / immunology
  • Male
  • Middle Aged
  • Natural Killer T-Cells / drug effects
  • Natural Killer T-Cells / immunology*
  • Viral Load / drug effects

Substances

  • Antiviral Agents
  • DNA, Viral
  • Hepatitis B e Antigens
  • Interleukin-4
  • entecavir
  • Guanine
  • Interferon-gamma